ANTITUBERCULOSIS DRUG DOSAGE FORMS: RANGE, KEY BENEFITS AND PROSPECTS OF TECHNOLOGICAL IMPROVEMENT

Interest to research in the development of new formulations of antituberculosis drugs due to the high incidence of tuberculosis in the Republic of Kazakhstan and the Russian Federation nowadays, including with acquired drug resistance. The reason for the development of acquired drug resistance is to interrupt the treatment of patients is the high toxicity of antituberculosis drugs. The improving the efficiency of antituberculosis therapy remains one of the most pressing.

The aim this study was to review the dosage forms of antituberculosis drugs currently used and the ways to improve them.

Methods. The study was conducted on the basis of scientific analysis (eLibrary database, PubMed, Cyberleninca), patent (kzpatents), reference (Klifar, Drugs register) and technical literature.

Results. It was revealed that the antituberculosis drugs are available in the form of tablets, capsules, granules for oral use and injection solutions. The advantages and disadvantages of oral dosage forms of antituberculosis drugs: tablets, capsules, granules, syrups, suspensions are described. The importance of the development and implementation in practice of pediatric formulations of antituberculosis drugs is mentioned. The state of current research inhaled formulations for the treatment of tuberculosis is described. The prospects of directional inhalation exposure by immobilization of antituberculosis drugs in liposomes, niosomes, nanocapsules, micelles, micro- and nanoparticles are mentioned. The prospect of the rectal formulations use is described. The increase in interest in the molecular encapsulation of medicinal substances with cyclodextrins in connection with the possibility of increasing the bioavailability of active ingredients, reduce the harmful effects on the gastrointestinal tract, extension, elimination of interaction of incompatible components in combination preparations, the protection of unstable substances is marked.

Conclusion: the analysis showed the possibility of improving the antituberculosis drugs by creating more comfortable for the reception in the different conditions of dosage forms, as well as the use of antituberculosis drugs immobilization for reducing toxicity, increasing bioavailability and sustained action.

1. Stop TB Partnership and World Health Organization. The Global Plan to Stop TB 2011–2015 / Geneva, World Health Organization, 2010. 89 p.

2. Global report on surveillance and response «Multidrug and extensively drug- resistant TB (M/XDR-TB)» / WHO, 2010. Р. 1–71.

3. Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009 / Geneva, World Health Organization, 2009 (WHO/HTM/TB/2009.411). 21 p.

4. Medicines for the treatment of drug-resistant tuberculosis under the microscope. Report of the International Union against tuberculosis and lung diseases. Geneva, 2011. – P. 46.

5. Cliphar. Internet-version of the State Register of drugs. Available at: http:// www.cliphar.ru/products/cliphar-gosreestr (in Russian).

6. Register of medicines (RLS). Available at: http://www.rlsnet.ru. (in Russian).

7. Tihonov A.I. Biopharmacy: academic for students Pharmaceutical universities and faculty. – H.: Izd-vo NfaU, 2003, 240 p. (in Russian).

8. Gazan V.V., Tovsultanov A.A., Emanova A.M. Analysis of the range of drugs used in the Chechen Republic. Development, research and marketing of pharmaceutical products: collected papers works. Pyatigorsk: PGFA, 2011. Vol. 66. P. 681–683 (in Russian).

9. Kulik V.V. Analysis of the status of the medicinal help sick tuberculosis. Development, research and marketing of pharmaceutical products: collected papers works. Pyatigorsk: PGFA, 2013, Vol. 68.P. 681–683. (in Russian).

10. Petrov A. Yu. The development of compositions and technological substantiation of the tablets of ethionamide. Ural medical review. 2001. No. 1 (32). P. 79–81. (in Russian.)

11. Ushakov V. A., Ovcharenko L. P., Kompantseva E. V., Kuznetsova L. The study of the composition and antimicrobial activity of granules containing isoniazid and ethambutol hydrochloride. Vestnik of Volgograd state medical University. 2006. No.1 (17). P. 55 – 59.

12. Morozova T.I., Parolina L.E., Doktorova N.P., Barinboim O.N. The efficacy of combined chemotherapy in the treatment of TB patients with a high risk of drug resistance m.tuberculosis. Bulletin of contemporary clinical medicine. 2013. Vol. 6, no. 2. P. 46–51 (in Russian).

13. Ramesh Panchagnula et al. Fixed-dose combinations for tuberculosis: lessons learned from a clinical, formulation and regulatory perspective. Department of Pharmaceutics National Institute of Pharmaceutical Education and Research (NIPER). India, 2004. P. 1–40.

14. Murzagulova K. B., Kim M. E., Tulegenov, A. O., R. S. Kuzenbaeva K To the question of stability of combined anti-TB drugs. Pharmacy Kazakhstan. 2009. No. 3. P. 18–22 (in Russian). Shevchenko A.M., Kovalevskaya E.G. Technological features of the development and production methods orodispersible tablets. Drug Development & Registration. 2015. No. 6. Available at: http://pharmjournal.ru/articles/stati.

15. Ushkalova E. The value of dosage forms for rational antibiotic therapy. Dosage form of Solutab. Doctor. 2007. No. 3. P. 63–66 (in Russian).

16. Kim M.E., Murzagulova К.B., Stepanova E.F. Bioavailability of drug Isoniazid- D tablets dispersible research. Fundamental research. 2014. No. 3 (p. 4). P. 766–769 (in Russian).

17. Kim M.E. et al. Comparative pharmacokinetics and relative bioavailability of the new domestic preparation RIZEF-D. Pharmacy Kazakhstan. 2010. No. 10. P. 18–21 (in Russian).

18. Pat 30327 RK Sagintaeva G. L. et al. Method of treatment of pulmonary tuberculosis. Available at: http://kzpatents. com/2015/06/15 (in Russian).

19. Kim M.E., Stepanova E.F., Evseeva S.B. Syrups: composition, technology, current state of research (review). Pharmacy & Pharmacology. 2014. №3 (4). P. 7-14. DOI http://dx.doi.org/10.19163/2307-9266-2014-2-3(4)-7-14. (in Russian).

20. Saenko A. Yu., Stepanova E. F., Olymsky I. S. Development of the composition of TB with ciprofloxacin syrup. Development, research and marketing of pharmaceutical products: collected papers works. Pyatigorsk: PGFA, 2006. Vol. 68. P. 131–132 (in Russian).

21. Isoniazid syrup. Yuri Farm. Products. Available at: http://www.uf.ua/product/yzonyazyd-syrop/ (in Russian).

22. Fisenko V. TB facilities: principles of action, side effects and prospects of development of new drugs. Doctor. 2006. No.12. P. 30-35. (in Russian).

23. Medvedev S.A., Naryshkina S.L. The efficacy of lecithin ultrapulse of anti-TB drugs in the treatment of newly diagnosed patients with pulmonary tuberculosis. Siberian medical review. 2009. Vol. 60, no. 6 (in Russian).

24. Tsubota N., Tanimukai S. A. Clinical experience of rifampicin suppository for the treatment of pulmonary tuberculosis. Kekkaku. 2015. Jun; 90(6). Р. 543–547.

25. Borisova O.A., Moldaver B.L., Aleksandrova A.E. The use of suppositories with rifampicin for treatment of tuberculosis. Pharmacy in the XXI century: innovations and traditions: proc. dokl. intern. scientific. conf., SPb, 1999. P. 49. (in Russian).

26. Boiko A.V. The use of aerosol therapy in patients with drug-resistant tuberculosis. The Actual infectology. 2014. № 4 (5). P. 70–74. (in Russian).

27. Shegokar Ranjita A., Shaal Loaye, Mitri Khalil Present status of nanoparticle research for treatment of tuberculosis. J Pharm Pharmaceut Sci (www.cspsCanada. org). 2011. Vol. 14(1). P. 100–116.

28. Maghraby Zh., Mozhokina G.N., Alyautdin R.N. et al. Development and pharmacological study of nanosomal forms of certain anti-TB drugs. Russian medical journal. 2012. No. 2. P. 33–35.

29. Hirayama F., Uekama K. Cyclodextrin-based controlled drug release system. Adv. Drug Deliv. Rev. 1999. No. 36. Р. 125–141.